Jasbir Seehra - 19 Feb 2026 Form 4 Insider Report for Keros Therapeutics, Inc. (KROS)

Role: CHIEF EXECUTIVE OFFICER, Director
Signature: /s/ Keith Regnante, Attorney-in-Fact
Issuer symbol: KROS
Transactions as of: 19 Feb 2026
Net transactions value: -$113,433
Form type: 4
Filing time: 20 Feb 2026, 16:15:17 UTC
Previous filing: 09 Jan 2026
Next filing: 26 Feb 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Seehra Jasbir	CHIEF EXECUTIVE OFFICER, Director	C/O KEROS THERAPEUTICS, INC., 1050 WALTHAM STREET, SUITE 302, LEXINGTON	/s/ Keith Regnante, Attorney-in-Fact	20 Feb 2026	0001732369

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	KROS	Common Stock	Sale	$113,433	-7,015	-1.8%	$16.17	385,708	19 Feb 2026	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The Issuer has adopted a "sell-to-cover" policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.